Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Bu yntem, topikal kremler ve serumlara kyasla daha derin penetrasyon ve artrlm biyoyararlanm salar
Add 2mL to a 10mg vial for 5mg/mL (5,000mcg/mL): 250mcg = 5 units, 500mcg = 10 units
The review reported that preclinical models involving surgically transected tendons, ligaments, and bone structures consistently reported associations between BPC157 exposure and accelerated structural repair, better-supported biomechanical strength indices, and better-supported collagen matrix organization
US$ 29.47
US$ 21.88
US$ 23.40